Mesoblast Limited (ASX:MSB) Insider Buys A$142,324.78 in Stock

Mesoblast Limited (ASX:MSB) insider Eric Rose bought 21,428 shares of the stock in a transaction that occurred on Tuesday, April 30th. The stock was acquired at an average price of A$6.64 ($4.40) per share, for a total transaction of A$142,324.78 ($94,254.82).

Mesoblast Stock Performance

The company has a quick ratio of 1.82, a current ratio of 2.71 and a debt-to-equity ratio of 23.98.

About Mesoblast

Mesoblast Limited engages in the development of regenerative medicine products in Australia, the United States, Singapore, and Switzerland. The company offers products in the areas of cardiovascular, spine orthopedic disorder, oncology, hematology, and immune-mediated and inflammatory diseases. Its proprietary regenerative medicine technology platform is based on specialized cells known as mesenchymal lineage cells.